Author: admin

  • Joanna Cherry – 2016 Parliamentary Question to the Foreign and Commonwealth Office

    Joanna Cherry – 2016 Parliamentary Question to the Foreign and Commonwealth Office

    The below Parliamentary question was asked by Joanna Cherry on 2016-06-08.

    To ask the Secretary of State for Foreign and Commonwealth Affairs, what representations he has made to the government of Burundi on (a) ending political violence and unrest and (b) alleged extra-judicial killings, torture, lack of freedom of expression and other human rights abuses in that country.

    James Duddridge

    I am extremely concerned about the situation in Burundi. During my visit to Bujumbura in December 2015 I emphasised to the Burundian Government that killings, torture and other abuses must stop and that they must take action to end impunity. I underlined the need for media, opposition and civil society to be allowed to operate freely and that all sides must renounce violence and participate fully in the dialogue. I repeated these messages in my letter to the Burundian Foreign Minister in May. Our Special Envoy for the Great Lakes Region reiterated these points in meetings with Burundian ministers in Bujumbura last week and during her visit to Arusha in May for the second round of the dialogue facilitated by former Tanzanian President Mkapa.

  • Tim Farron – 2016 Parliamentary Question to the Department of Health

    Tim Farron – 2016 Parliamentary Question to the Department of Health

    The below Parliamentary question was asked by Tim Farron on 2016-06-08.

    To ask the Secretary of State for Health, how much the NHS spent on treating people with medical conditions caused by botox injections in the last five years.

    Ben Gummer

    Information is not held on National Health Service spending on treating people with medical conditions caused by botox injections.

  • Jim Cunningham – 2016 Parliamentary Question to the Department of Health

    Jim Cunningham – 2016 Parliamentary Question to the Department of Health

    The below Parliamentary question was asked by Jim Cunningham on 2016-06-08.

    To ask the Secretary of State for Health, what the most expensive drugs bought from pharmaceutical companies by the NHS were in the last five years; and if he will make a statement.

    Alistair Burt

    Based on National Health Service list prices at launch notified to the Department between 2009 and 2015 under the rules of the Pharmaceutical Price Regulation Scheme and statutory regulations, the 10 most expensive medicines in terms of list price per pack are shown in the table.

    In considering the impact of a medicine, it is important to take into account both the product’s total net costs and the net health benefits it generates.

    Product

    Manufacturer

    Strensiq (asfotase alfa) 80mg injection

    Alexion

    Translarna (ataluren) granules for oral suspension

    PTC Therapeutics Ltd

    Sirturo (bedaquiline fumarate) tablets

    Janssen-Cilag Ltd

    Lojuxta (lomitapide) capsules

    Aegerion Pharmaceuticals

    Provenge (sipuleucel-T) dispersion for infusion

    Dendreon Coporation

    ChondroCelect (characterised viable autologous cartilage cells expanded exvivo) implantation suspension

    Swedish Orphan Biovitrum (SOBI)

    Yervoy (ipilimumab) vials

    Bristol-Myers Squibb UK

    Revestive (teduglutide) injection

    NPS Pharma International

    Kalydeco (ivacaftor) tablets

    Vertex Pharmaceuticals

    Kalydeco (ivacaftor) oral granules

    Vertex Pharmaceuticals

    Source: Department of Health

  • Jim Cunningham – 2016 Parliamentary Question to the Department of Health

    Jim Cunningham – 2016 Parliamentary Question to the Department of Health

    The below Parliamentary question was asked by Jim Cunningham on 2016-06-08.

    To ask the Secretary of State for Health, what estimate his Department has made of the average price paid by the NHS for prescription drugs in each of the last 10 years; and if he will make a statement.

    Alistair Burt

    The average net ingredient cost of prescription items dispensed in the community in England is in the table: Information for medicines supplied in secondary care is not available.

    Year

    Average net ingredient cost
    per prescription item (£)

    2005

    11.02

    2006

    10.90

    2007

    10.51

    2008

    9.88

    2009

    9.64

    2010

    9.53

    2011

    9.16

    2012

    8.52

    2013

    8.37

    2014

    8.32

    2015

    8.55

    Source: Prescription Cost Analysis data provided by the Health and Social Care Information Centre

  • Jim Cunningham – 2016 Parliamentary Question to the Department of Health

    Jim Cunningham – 2016 Parliamentary Question to the Department of Health

    The below Parliamentary question was asked by Jim Cunningham on 2016-06-08.

    To ask the Secretary of State for Health, what estimate his Department has made of the amount paid by the NHS to pharmaceutical companies for prescription drugs in each of the last 10 years; and if he will make a statement.

    Alistair Burt

    The information requested is in the table.

    Year

    Primary care drugs spend (1)

    Secondary care drugs spend

    Total drugs spend

    Outturn (£ m)

    Outturn (£ m)

    Outturn (£ m)

    2004/05

    7,376

    2,595

    9,971

    2005/06

    7,235

    2,764

    9,999

    2006/07

    7,593

    2,969

    10,562

    2007/08

    7,663

    3,274

    10,937

    2008/09

    7,749

    3,647

    11,397

    2009/10

    7,946

    3,974

    11,920

    2010/11

    8,280

    4,257

    12,537

    2011/12

    8,243

    4,482

    12,725

    2012/13(2)

    7,887

    5,055

    12,941

    2013/14(3)

    8,015

    5,324

    13,339

    2014/15

    8,206

    5,897

    14,103

    Sources:

    1. Primary care figures to 2012-13 are from Primary Care Trusts (PCTs) audited summarisation schedules. Figures from 2013-14 are from the Department’s annual report and accounts.
    2. Secondary care figures are from National Health Service trusts, PCT finance returns and foundation trust year-end accounts. Finance returns were not collected after 2011/12; figures for NHS trusts in 2012/13 are estimates.
    3. Secondary care figures from 2013-14 are from Monitor and NHS Trust Development Authority.
  • Philip Davies – 2016 Parliamentary Question to the Department of Health

    Philip Davies – 2016 Parliamentary Question to the Department of Health

    The below Parliamentary question was asked by Philip Davies on 2016-06-08.

    To ask the Secretary of State for Health, how much the NHS spent on interpreters in each of the last three years.

    Alistair Burt

    This information is not held centrally.

  • Tim Farron – 2016 Parliamentary Question to the Department of Health

    Tim Farron – 2016 Parliamentary Question to the Department of Health

    The below Parliamentary question was asked by Tim Farron on 2016-06-08.

    To ask the Secretary of State for Health, whether he plans to increase the provision of respite and replacement care for carers in England.

    Alistair Burt

    The Government recognises the invaluable contribution made by unpaid carers and the importance of supporting them in their carer roles. This includes provision of and access to respite and replacement care.

    The Department has provided £400 million to the National Health Service over four years from 2011 for carers to have breaks from their caring responsibilities. The carers breaks funding of £130 million is now included in the Better Care Fund in 2016/17. The Department has also provided £186.6 million of funding in 2016/17 to local authorities for improved carers’ rights, as established in the Care Act 2014.

    The Care Act 2014 duty for local authorities to undertake carers’ assessments also provides an opportunity for the local authority and the carer to look at the support they need and the outcomes that they wish to achieve, including providing them with a break or taking up work, educational and leisure opportunities if they wish.

    The Department is committed to continuing to improve support for carers and is currently leading the development of a new cross-Government national carers’ strategy, due to be published by the end of 2016. We are currently consulting widely with a range of stakeholders and carers themselves to inform the development of the strategy.

  • Tim Farron – 2016 Parliamentary Question to the Department of Health

    Tim Farron – 2016 Parliamentary Question to the Department of Health

    The below Parliamentary question was asked by Tim Farron on 2016-06-08.

    To ask the Secretary of State for Health, what steps he is taking to develop a cross-departmental strategy to provide more support to carers in England.

    Alistair Burt

    The Government recognises the invaluable contribution made by unpaid carers and the importance of supporting them in their carer roles. This includes provision of and access to respite and replacement care.

    The Department has provided £400 million to the National Health Service over four years from 2011 for carers to have breaks from their caring responsibilities. The carers breaks funding of £130 million is now included in the Better Care Fund in 2016/17. The Department has also provided £186.6 million of funding in 2016/17 to local authorities for improved carers’ rights, as established in the Care Act 2014.

    The Care Act 2014 duty for local authorities to undertake carers’ assessments also provides an opportunity for the local authority and the carer to look at the support they need and the outcomes that they wish to achieve, including providing them with a break or taking up work, educational and leisure opportunities if they wish.

    The Department is committed to continuing to improve support for carers and is currently leading the development of a new cross-Government national carers’ strategy, due to be published by the end of 2016. We are currently consulting widely with a range of stakeholders and carers themselves to inform the development of the strategy.

  • Andrew Smith – 2016 Parliamentary Question to the Department of Health

    Andrew Smith – 2016 Parliamentary Question to the Department of Health

    The below Parliamentary question was asked by Andrew Smith on 2016-06-08.

    To ask the Secretary of State for Health, how the proportion of each Sustainability and Transformation Plan area’s total place-based target allocation was calculated.

    George Freeman

    The proportion was calculated by adding together the place-based target allocation in 2020/21 for each of the clinical commissioning group (CCG) areas within a Sustainability and Transformation Plan footprint, and expressing that total as a percentage of the total national place-based target allocation in 2020/21.

    Figures by CCG area for place-based target allocations are available at:

    https://www.england.nhs.uk/wp-content/uploads/2016/01/total-place-allocations.pdf

    “

  • Jim Cunningham – 2016 Parliamentary Question to the Department of Health

    Jim Cunningham – 2016 Parliamentary Question to the Department of Health

    The below Parliamentary question was asked by Jim Cunningham on 2016-06-08.

    To ask the Secretary of State for Health, what the largest financial contracts between the NHS and pharmaceutical companies were in each of the last five years; and if he will make a statement.

    Alistair Burt

    Details of the largest1 financial contracts between the National Health Service and pharmaceutical companies in each of the last five calendar years are given in the table:

    Year

    Supplier Name

    Department of Health Tender Reference

    Framework Agreement Title

    2011

    Gilead Sciences Ltd

    CM/PHR/08/5000

    Pharmaceuticals Antiretroviral pan-London April 2010

    2012

    Gilead Sciences Ltd

    CM/PHR/10/5203

    Pan London Antiretroviral

    2013

    Gilead Sciences Ltd

    CM/PHR/10/5203

    Pan London Antiretroviral

    2014

    Gilead Sciences Ltd

    CM/PHR/10/5203

    Pan London Antiretroviral

    2015

    Pfizer Limited

    CM/PHR/13/5415

    Branded Pharmaceutical Products – National (05-2014)

    Source: Department of Health Commercial Medicines Unit

    1 Based on pre-agreement estimated values for framework agreements for the use of hospitals in England.